Related Experiment Video
Updated: May 25, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia
Manfredi Rizzo1, Giovam Battista Rini
1Department of Internal Medicine and Medical Specialties, University of Palermo, Italy.
Archives of Medical Science : AMS
|February 1, 2012
Summary
Ezetimibe effectively lowers low-density lipoprotein (LDL) cholesterol but shows limited impact on atherosclerosis progression and cardiovascular events. Further outcome trials are needed to fully understand its long-term clinical benefits.
Area of Science:
- Cardiology
- Pharmacology
- Atherosclerosis Research
Background:
- Ezetimibe is a cholesterol absorption inhibitor that reduces LDL cholesterol.
- It demonstrates efficacy in monotherapy and combination with statins/fibrates.
- Its impact on atherogenic dyslipidemia and clinical outcomes requires further investigation.
Purpose of the Study:
- To evaluate the effects of ezetimibe on LDL cholesterol levels.
- To assess the impact of ezetimibe on atherosclerosis progression and cardiovascular events.
- To analyze the role of ezetimibe in managing hypercholesterolemia.
Main Methods:
- Review of findings from the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) study.
- Analysis of data from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study.
- Consideration of ongoing formal cardiovascular outcome trials.
Main Results:
- Ezetimibe significantly reduces LDL cholesterol by 15-25%.
- The ENHANCE study showed no effect on carotid intima-media thickness despite LDL reduction.
- The SEAS study indicated no impact on major cardiovascular events but reduced ischemic events.
Conclusions:
- Ezetimibe primarily causes quantitative LDL reduction with limited qualitative changes in atherogenic dyslipidemia.
- Current evidence suggests ezetimibe's effect on clinical outcomes beyond LDL reduction is modest.
- Long-term cardiovascular outcome trials are essential for a comprehensive understanding of ezetimibe's clinical utility.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:29Cholesterol: Significance and Regulation
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:18Lipids: Dietary Sources and Requirements
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ meats, shellfish,...
01:24Lipid Absorption
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...